Korro Bio, Inc.

NASDAQ•KRRO

CEO: Mr. Nessan Bermingham Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2019-10-03

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

連絡先情報

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, MA, 02139, United States

617-468-1999

www.korrobio.com

時価総額

$128.59M

PER (TTM)

-1.1

配当利回り

52週高値

$55.89

52週安値

$5.20

52週レンジ

17%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

8年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2018-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.29M+0.00%

直近4四半期の推移

EPS

-$5.33+0.00%

直近4四半期の推移

フリーCF

-$17.79M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Collaboration Revenue Increased Collaboration revenue reached $6.4M USD in 2025, up $4.1M USD from $2.3M USD in 2024, driven by Novo Nordisk agreement.

KRRO-121 Advancement Progressing Lead candidate KRRO-121 targets hyperammonemia with regulatory filing anticipated in the second half of 2026 for first-in-human trial.

AATD Candidate Nomination Nearing Next-generation AATD program expects development candidate nomination in the second quarter of 2026 following pivot to GalNAc delivery.

Cash Runway Extended Cash runway extends into the second half of 2028 supporting key milestones after recent financing activities and restructuring efforts.

リスク要因

Continued Operating Losses Expected Net loss widened to $(117.3M) USD in 2025 from $(83.6M) USD in 2024; expects increasing expenses and negative cash flow indefinitely.

Significant Asset Impairment Recognized $30.9M USD non-cash impairment charge in Q4 2025 related to operating lease and fixed assets following program termination.

Pipeline Concentration Risk High Business heavily reliant on KRRO-121 success; only nominated candidate after terminating KRRO-110 program due to insufficient functional protein levels.

Novel Technology Unproven RNA editing technology is new with limited clinical validation; preclinical success does not guarantee positive results in human trials.

見通し

Advance KRRO-121 Clinical Trial Anticipate regulatory filing for KRRO-121 in H2 2026 to commence first-in-human trial for hyperammonemia treatment indications.

Optimize OPERA Platform Further Continue enhancing OPERA platform using computational models and new data to expedite design and optimization of future lead candidates.

Advance ALS and Longevity Programs Continue advancing ALS program targeting TDP-43 aggregation and longevity program targeting AMPKγ1 activation through preclinical studies.

Seek Strategic Partnerships Plan to actively seek innovative collaborations and strategic alliances to maximize OPERA platform potential across rare and prevalent diseases.

同業比較

売上高 (TTM)

AMRN

$183.87M

-19.6%

ADCT

$81.36M

+14.9%

AUTL

$75.35M

+644.6%

粗利益率 (最新四半期)

AMRN

119.2%

+7.3pp

ALT

100.0%

-299200.0pp

ADCT

84.5%

-2.7pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
RAPT	$959.26M	-14.8	-61.8%	1.6%
ANNX	$759.43M	-4.8	-101.3%	9.4%
ADCT	$555.18M	-4.6	66.2%	135.9%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-20.3%

成長鈍化

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし